Cathay Biotech (SH:688065) Zhong Guo Jing Ji Wang·2025-10-16 08:23Core Points - Kaisa Bio's stock closed at 48.63 yuan, with a decline of 3.07%, currently in a breaking state [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 12, 2020, with an initial public offering (IPO) price of 133.45 yuan per share [1][2] - The highest price recorded on the first trading day was 198 yuan, marking the peak since its listing [2] - Kaisa Bio raised a total of 556.06 million yuan during its IPO, with a net amount of 528 million yuan, exceeding the original fundraising plan by 58.11 million yuan [2] - The funds raised are intended for various projects, including a 40,000 tons/year bio-based dodecanedioic acid project and a research center for bio-based polyamide [2] - The total issuance costs for the IPO amounted to 28.06 million yuan, with the underwriter, CITIC Securities, receiving 26.23 million yuan [2] - In July 2022, Kaisa Bio announced a dividend of 4.5 yuan per 10 shares and a stock bonus of 4 shares [2] - The actual controllers of Kaisa Bio are Liu Xiucai, Ma Xiaowen, and Charlie Chi Liu, who are American citizens of Chinese descent [2] - On March 28, 2025, Kaisa Bio disclosed a report on a private placement of A-shares, raising approximately 5.93 billion yuan from its controlling shareholder, Shanghai Yaoxiu [3] - The total amount raised from the two fundraising activities is 11.49 billion yuan [4]